Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine.
Brain research November 13, 1999 DOI: 10.1016/s0006-8993(99)02017-x via PubMed
Summary
AI-generated from the abstractIbogaine, a psychoactive alkaloid from the shrub Tabernanthe iboga used to treat stimulant addiction, does not by itself alter dynorphin levels in key brain regions such as the striatum, substantia nigra, or nucleus accumbens. However, when given before cocaine, ibogaine dramatically amplifies cocaine-induced increases in dynorphin content in those same structures. This suggests ibogaine may influence addiction-related brain pathways by modulating dynorphin responses to cocaine, offering insights into its anti-addiction potential.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats (implied by typical neuroscience methods, but not stated) |
| Interventions | Ibogaine Cocaine |
| Topics | Ibogaine |
| Keywords | Natural compound Cocaine addiction Stimulant Neuroscience |
| Citations | 11 |
| Key finding | Ibogaine pretreatment dramatically enhanced cocaine-induced increases in dynorphin content in the striatum, substantia nigra, and nucleus accumbens, whereas ibogaine alone did not alter dynorphin levels. |
Abstract
Ibogaine (Endabuse) is a psychoactive indole alkaloid found in the shrub, Tabernanthe iboga, which has been used to treat stimulant addiction. Because ibogaine influences the activity of neurotensin systems, a dopamine-linked neuropeptide, the present study investigated if ibogaine also influences dynorphin (DYN) pathways. Unlike neurotensin responses, ibogaine alone did not alter DYN levels in the striatum, substantia nigra or nucleus accumbens. Interestingly, ibogaine pretreatment dramatically enhanced cocaine-induced increases in DYN content in these structures.